About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Men and Women and Science and Jobs | Main | Bubble Fusion Implodes »

March 9, 2006

Wonder Drug, Indeed

Email This Entry

Posted by Derek

"Wonder Drug Inspires Deep, Unwavering Love of Pharmaceutical Companies":

"Many individuals today lack the deep, abiding affection for drug makers that is found in healthy people, such as myself," Pfizer CEO Hank McKinnell said. "These tragic disorders are reaching epidemic levels, and as a company dedicated to promoting the health, well-being, and long life of our company's public image, it was imperative that we did something to combat them". . .

. . .PharmAmorin is the first drug of its kind, but Pfizer will soon face competition from rival pharmaceutical giant Bristol-Myers Squibb. The company is developing its own pro-pharmaceutical-company medication, Brismysquibicin, which will induce warm feelings not just for drug corporations in general, but solely for Bristol-Myers Squibb.

Now that last one would be a real challenge. Of course, you've got to wonder what your rodent efficacy model for something like this would be. . .

Comments (8) + TrackBacks (0) | Category:


1. NJBiologist on March 10, 2006 7:10 AM writes...

How to do an animal model? I imagine you'd have to use a conditioned place preference model with the different corporate logos on the walls, and measure time spent under the BMS logo vs. the Pfizer logo, etc.

This is just about the funniest thing the Onion has done since... well... Sucrosa(TM).

Permalink to Comment

2. Doc Bushwell on March 10, 2006 7:21 AM writes...

As a news vehicle aimed at a general audience, The Onion fails to mention the mechanism of action for PharmAmorin and Brismysquibicin. The biological target is found within the gene family of GPRRs (Good Public Relations Receptor). Because of stringent species specificity, no rodent efficacy models exist, and clinical trials were direct to man. Still, non-human species tox studies must be performed, and from an insider’s perspective, I can tell you that those for Brismysquibicin were most disconcerting. A vivarium tech was found smothered in the residue of rat-love. It was ugly, man...ugly.

Permalink to Comment

3. Phil-Z on March 10, 2006 8:32 AM writes...

This post is about 3 weeks early, isn't it?

Permalink to Comment

4. Doc Bushwell on March 10, 2006 8:35 AM writes... clarify, the off target activity of Brismysquibicin is the enzyme rattusunnaturallustase (EC

Permalink to Comment

5. Robin Goodfellow on March 10, 2006 1:06 PM writes...

The problem with Brismysquibicin is that it has a limited shelf-life. What happens when Bristol-Myers-Squibb inevitably becomes Bristol-Myers-Squibb-Pfizer, or somesuch, for example?

In a more serious note, slightly, I think that the advent of ED drugs like Viagra has probably done more for big-pharma PR than anything else. Which is very ironic when you think about it. Coming up with life-saving wonder cures for AIDS, cancer, and other diseases merely earns heaps of scorn for having the gall to charge money for the stuff. But quality of life fun-pills like Viagra win respect, admiration, and thanks.

Permalink to Comment

6. Katherine on March 10, 2006 4:35 PM writes...

I fail to understand how PhRMA can be doing such a colossally bad job of PR. It has plenty of money and great source material, and yet the individual pharmas are the ones putting out warm-fuzzy ads and advertising their own patient assistance programs. I don't get it.

Permalink to Comment

7. Anonymous on March 12, 2006 6:15 PM writes...

I'm sure that a "critical thinking inhibitor" could have many other uses as well. Seems like something that a politician would love to have, for example.

Permalink to Comment

8. Jack on March 16, 2006 11:10 AM writes...

While drugs certainly play an important role in our society,i'd like to see more emphasis put on individuals taking better care of themselves through diet and exercise.

Permalink to Comment


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry